請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/70043
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 林水龍 | zh_TW |
dc.contributor.advisor | Shuei-Liong Lin | en |
dc.contributor.author | 邵鈺涵 | zh_TW |
dc.contributor.author | Yu-Han Shao | en |
dc.date.accessioned | 2021-06-17T03:40:24Z | - |
dc.date.available | 2023-12-15 | - |
dc.date.copyright | 2018-03-29 | - |
dc.date.issued | 2018 | - |
dc.date.submitted | 2002-01-01 | - |
dc.identifier.citation | 1. Dalezios, Y., et al., Anatomy and physiology of the primate interstitial nucleus of Cajal. II. Discharge pattern of single efferent fibers. J Neurophysiol, 1998. 80(6): p. 3100-11.
2. Klingberg, A., et al., Fully Automated Evaluation of Total Glomerular Number and Capillary Tuft Size in Nephritic Kidneys Using Lightsheet Microscopy. J Am Soc Nephrol, 2017. 28(2): p. 452-459. 3. Puelles, V.G., et al., Glomerular number and size variability and risk for kidney disease. Curr Opin Nephrol Hypertens, 2011. 20(1): p. 7-15. 4. Zhang, J.L., et al., Functional MRI of the kidneys. J Magn Reson Imaging, 2013. 37(2): p. 282-93. 5. Scott, R.P. and S.E. Quaggin, Review series: The cell biology of renal filtration. J Cell Biol, 2015. 209(2): p. 199-210. 6. White, K.E., Research into the structure of the kidney glomerulus--making it count. Micron, 2012. 43(10): p. 1001-9. 7. Knepper, M. and M. Burg, Organization of nephron function. Am J Physiol, 1983. 244(6): p. F579-89. 8. Jin, R., et al., Estimated glomerular filtration rate and renal function. Ann Thorac Surg, 2008. 86(1): p. 1-3. 9. Osgood, R.W., H.J. Reineck, and J.H. Stein, Methodologic considerations in the study of glomerular ultrafiltration. Am J Physiol, 1982. 242(1): p. F1-7. 10. Denton, K.M., et al., Differential neural control of glomerular ultrafiltration. Clin Exp Pharmacol Physiol, 2004. 31(5-6): p. 380-6. 11. Deen, W.M., et al., Dynamics of glomerular ultrafiltration in the rat. IV. Determination of the ultrafiltration coefficient. J Clin Invest, 1973. 52(6): p. 1500-8. 12. Fischer, K., et al., Renal ultrafiltration changes induced by focused US. Radiology, 2009. 253(3): p. 697-705. 13. Grahammer, F., C. Schell, and T.B. Huber, Molecular understanding of the slit diaphragm. Pediatr Nephrol, 2013. 28(10): p. 1957-62. 14. Deen, W.M., M.J. Lazzara, and B.D. Myers, Structural determinants of glomerular permeability. Am J Physiol Renal Physiol, 2001. 281(4): p. F579-96. 15. Haraldsson, B., J. Nystrom, and W.M. Deen, Properties of the glomerular barrier and mechanisms of proteinuria. Physiol Rev, 2008. 88(2): p. 451-87. 16. W, K. and K. B, The Kidney Physiology and Pathophysiology. Structural organization of the mammalian kidney, ed. S. GW and G. G. 1992: New York: Raven. p. 707-777. 17. M, S. and S. N, Handbook of Physiology. The Cardiovascular System. . Ultrastructure of the microvascular wall: functional correlations. 1984. 18. Abrahamson, D.R., Role of the podocyte (and glomerular endothelium) in building the GBM. Semin Nephrol, 2012. 32(4): p. 342-9. 19. Miner, J.H., Glomerular basement membrane composition and the filtration barrier. Pediatr Nephrol, 2011. 26(9): p. 1413-7. 20. Laurie, G.W., et al., Fine structure of the glomerular basement membrane and immunolocalization of five basement membrane components to the lamina densa (basal lamina) and its extensions in both glomeruli and tubules of the rat kidney. Am J Anat, 1984. 169(4): p. 463-81. 21. Candiello, J., G.J. Cole, and W. Halfter, Age-dependent changes in the structure, composition and biophysical properties of a human basement membrane. Matrix Biol, 2010. 29(5): p. 402-10. 22. Robinson, G.B. and H.A. Walton, Glomerular basement membrane as a compressible ultrafilter. Microvasc Res, 1989. 38(1): p. 36-48. 23. Salmon, A.H., C.R. Neal, and S.J. Harper, New aspects of glomerular filtration barrier structure and function: five layers (at least) not three. Curr Opin Nephrol Hypertens, 2009. 18(3): p. 197-205. 24. Arkill, K.P., et al., Resolution of the three dimensional structure of components of the glomerular filtration barrier. BMC Nephrol, 2014. 15: p. 24. 25. Borza, C.M. and A. Pozzi, The role of cell-extracellular matrix interactions in glomerular injury. Exp Cell Res, 2012. 318(9): p. 1001-10. 26. Zent, R., et al., Glomerular injury is exacerbated in diabetic integrin alpha1-null mice. Kidney Int, 2006. 70(3): p. 460-70. 27. Pozzi, A., et al., Regulation of matrix synthesis, remodeling and accumulation in glomerulosclerosis. Curr Pharm Des, 2009. 15(12): p. 1318-33. 28. Hynes, R.O., The extracellular matrix: not just pretty fibrils. Science, 2009. 326(5957): p. 1216-9. 29. Pozzi, A., et al., Beta1 integrin expression by podocytes is required to maintain glomerular structural integrity. Dev Biol, 2008. 316(2): p. 288-301. 30. Vogtlander, N.P., et al., Localization of alpha-dystroglycan on the podocyte: from top to toe. J Histochem Cytochem, 2005. 53(11): p. 1345-53. 31. Greka, A. and P. Mundel, Cell biology and pathology of podocytes. Annu Rev Physiol, 2012. 74: p. 299-323. 32. Pavenstadt, H., W. Kriz, and M. Kretzler, Cell biology of the glomerular podocyte. Physiol Rev, 2003. 83(1): p. 253-307. 33. Reiser, J. and M.M. Altintas, Podocytes. F1000Research, 2016. 5. 34. Ichimura, K., H. Kurihara, and T. Sakai, Actin filament organization of foot processes in rat podocytes. J Histochem Cytochem, 2003. 51(12): p. 1589-600. 35. Mundel, P. and J. Reiser, Proteinuria: an enzymatic disease of the podocyte? Kidney Int, 2010. 77(7): p. 571-80. 36. Ruotsalainen, V., et al., Nephrin is specifically located at the slit diaphragm of glomerular podocytes. Proc Natl Acad Sci U S A, 1999. 96(14): p. 7962-7. 37. Schwarz, K., et al., Podocin, a raft-associated component of the glomerular slit diaphragm, interacts with CD2AP and nephrin. J Clin Invest, 2001. 108(11): p. 1621-9. 38. Grahammer, F., C. Schell, and T.B. Huber, The podocyte slit diaphragm--from a thin grey line to a complex signalling hub. Nat Rev Nephrol, 2013. 9(10): p. 587-98. 39. Huber, T.B. and T. Benzing, The slit diaphragm: a signaling platform to regulate podocyte function. Curr Opin Nephrol Hypertens, 2005. 14(3): p. 211-6. 40. Singh, A. and S.C. Satchell, Microalbuminuria: causes and implications. Pediatr Nephrol, 2011. 26(11): p. 1957-65. 41. National Kidney, F., K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis, 2002. 39(2 Suppl 1): p. S1-266. 42. Cravedi, P. and G. Remuzzi, Pathophysiology of proteinuria and its value as an outcome measure in chronic kidney disease. Br J Clin Pharmacol, 2013. 76(4): p. 516-23. 43. Wanner, N., et al., Unraveling the role of podocyte turnover in glomerular aging and injury. J Am Soc Nephrol, 2014. 25(4): p. 707-16. 44. Wu, M.T., et al., Albuminuria, proteinuria, and urinary albumin to protein ratio in chronic kidney disease. J Clin Lab Anal, 2012. 26(2): p. 82-92. 45. Reiser, J. and M.M. Altintas, Podocytes. F1000Res, 2016. 5. 46. Nagata, M., Podocyte injury and its consequences. Kidney Int, 2016. 89(6): p. 1221-30. 47. Mundel, P. and S.J. Shankland, Podocyte biology and response to injury. J Am Soc Nephrol, 2002. 13(12): p. 3005-15. 48. Wharram, B.L., et al., Podocyte depletion causes glomerulosclerosis: diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene. J Am Soc Nephrol, 2005. 16(10): p. 2941-52. 49. Buch, T., et al., A Cre-inducible diphtheria toxin receptor mediates cell lineage ablation after toxin administration. Nat Methods, 2005. 2(6): p. 419-26. 50. Ballermann, B.J., Glomerular endothelial cell differentiation. Kidney Int, 2005. 67(5): p. 1668-71. 51. Fierlbeck, W., et al., Endothelial cell apoptosis during glomerular capillary lumen formation in vivo. J Am Soc Nephrol, 2003. 14(5): p. 1349-54. 52. Robert, B., X. Zhao, and D.R. Abrahamson, Coexpression of neuropilin-1, Flk1, and VEGF(164) in developing and mature mouse kidney glomeruli. Am J Physiol Renal Physiol, 2000. 279(2): p. F275-82. 53. Fogo, A.B. and V. Kon, The glomerulus--a view from the inside--the endothelial cell. Int J Biochem Cell Biol, 2010. 42(9): p. 1388-97. 54. Navar, L.G., Glomerular permeability: a never-ending saga. Am J Physiol Renal Physiol, 2009. 296(6): p. F1266-8. 55. Satchell, S.C. and F. Braet, Glomerular endothelial cell fenestrations: an integral component of the glomerular filtration barrier. Am J Physiol Renal Physiol, 2009. 296(5): p. F947-56. 56. Quaggin, S.E. and J.A. Kreidberg, Development of the renal glomerulus: good neighbors and good fences. Development, 2008. 135(4): p. 609-20. 57. Curry, F.E. and R.H. Adamson, Endothelial glycocalyx: permeability barrier and mechanosensor. Ann Biomed Eng, 2012. 40(4): p. 828-39. 58. Hjalmarsson, C., B.R. Johansson, and B. Haraldsson, Electron microscopic evaluation of the endothelial surface layer of glomerular capillaries. Microvasc Res, 2004. 67(1): p. 9-17. 59. Jeansson, M. and B. Haraldsson, Morphological and functional evidence for an important role of the endothelial cell glycocalyx in the glomerular barrier. Am J Physiol Renal Physiol, 2006. 290(1): p. F111-6. 60. Satchell, S.C. and J.E. Tooke, What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium? Diabetologia, 2008. 51(5): p. 714-25. 61. Fu, J., et al., Glomerular endothelial cell injury and cross talk in diabetic kidney disease. Am J Physiol Renal Physiol, 2015. 308(4): p. F287-97. 62. Roberts, W.G. and G.E. Palade, Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci, 1995. 108 ( Pt 6): p. 2369-79. 63. Verma, S.K. and B.A. Molitoris, Renal endothelial injury and microvascular dysfunction in acute kidney injury. Semin Nephrol, 2015. 35(1): p. 96-107. 64. Woolf, A.S., L. Gnudi, and D.A. Long, Roles of angiopoietins in kidney development and disease. J Am Soc Nephrol, 2009. 20(2): p. 239-44. 65. Sugimoto, H., et al., Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem, 2003. 278(15): p. 12605-8. 66. Jeansson, M., et al., Angiopoietin-1 is essential in mouse vasculature during development and in response to injury. J Clin Invest, 2011. 121(6): p. 2278-89. 67. Zhong, F., et al., Reduced Kruppel-Like Factor 2 Aggravates Glomerular Endothelial Cell Injury and Kidney Disease in Mice with Unilateral Nephrectomy. Am J Pathol, 2016. 186(8): p. 2021-2031. 68. Goldwich, A., et al., Impairment of podocyte function by diphtheria toxin--a new reversible proteinuria model in mice. Lab Invest, 2012. 92(12): p. 1674-85. 69. Drawz, P.E. and M.E. Rosenberg, Slowing progression of chronic kidney disease. Kidney Int Suppl (2011), 2013. 3(4): p. 372-376. 70. Brosius, F.C. and R.J. Coward, Podocytes, signaling pathways, and vascular factors in diabetic kidney disease. Adv Chronic Kidney Dis, 2014. 21(3): p. 304-10. 71. USRDS: the United States Renal Data System. Am J Kidney Dis, 2003. 42(6 Suppl 5): p. 1-230. 72. Rocco, M.V. and J.S. Berns, KDOQI in the era of global guidelines. Am J Kidney Dis, 2009. 54(5): p. 781-7. 73. Reidy, K., et al., Molecular mechanisms of diabetic kidney disease. J Clin Invest, 2014. 124(6): p. 2333-40. 74. Seaquist, E.R., et al., Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med, 1989. 320(18): p. 1161-5. 75. Freedman, B.I., A.B. Tuttle, and B.J. Spray, Familial predisposition to nephropathy in African-Americans with non-insulin-dependent diabetes mellitus. Am J Kidney Dis, 1995. 25(5): p. 710-3. 76. Sandholm, N., et al., New susceptibility loci associated with kidney disease in type 1 diabetes. PLoS Genet, 2012. 8(9): p. e1002921. 77. Igo, R.P., Jr., et al., Genomewide linkage scan for diabetic renal failure and albuminuria: the FIND study. Am J Nephrol, 2011. 33(5): p. 381-9. 78. Kottgen, A., et al., New loci associated with kidney function and chronic kidney disease. Nat Genet, 2010. 42(5): p. 376-84. 79. Maurano, M.T., et al., Systematic localization of common disease-associated variation in regulatory DNA. Science, 2012. 337(6099): p. 1190-5. 80. Wendt, T.M., et al., RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol, 2003. 162(4): p. 1123-37. 81. Brownlee, M., Biochemistry and molecular cell biology of diabetic complications. Nature, 2001. 414(6865): p. 813-20. 82. Brownlee, M., The pathobiology of diabetic complications: a unifying mechanism. Diabetes, 2005. 54(6): p. 1615-25. 83. Lin, C.L., et al., Ras modulation of superoxide activates ERK-dependent fibronectin expression in diabetes-induced renal injuries. Kidney Int, 2006. 69(9): p. 1593-600. 84. Susztak, K., et al., Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes, 2006. 55(1): p. 225-33. 85. Rutkowski, J.M., et al., Adiponectin promotes functional recovery after podocyte ablation. J Am Soc Nephrol, 2013. 24(2): p. 268-82. 86. Sharma, K., et al., Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest, 2008. 118(5): p. 1645-56. 87. Susztak, K., et al., Multiple metabolic hits converge on CD36 as novel mediator of tubular epithelial apoptosis in diabetic nephropathy. PLoS Med, 2005. 2(2): p. e45. 88. Welsh, G.I., et al., Insulin signaling to the glomerular podocyte is critical for normal kidney function. Cell Metab, 2010. 12(4): p. 329-40. 89. Woroniecki, R., A.B. Gaikwad, and K. Susztak, Fetal environment, epigenetics, and pediatric renal disease. Pediatr Nephrol, 2011. 26(5): p. 705-11. 90. El-Osta, A., et al., Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med, 2008. 205(10): p. 2409-17. 91. Reddy, M.A. and R. Natarajan, Epigenetics in diabetic kidney disease. J Am Soc Nephrol, 2011. 22(12): p. 2182-5. 92. Ko, Y.A. and K. Susztak, Epigenomics: the science of no-longer-junk DNA. Why study it in chronic kidney disease? Semin Nephrol, 2013. 33(4): p. 354-62. 93. Ko, Y.A., et al., Cytosine methylation changes in enhancer regions of core pro-fibrotic genes characterize kidney fibrosis development. Genome Biol, 2013. 14(10): p. R108. 94. Siddiqi, F.S. and A. Advani, Endothelial-podocyte crosstalk: the missing link between endothelial dysfunction and albuminuria in diabetes. Diabetes, 2013. 62(11): p. 3647-55. 95. White, K.E., et al., Podocyte number in normotensive type 1 diabetic patients with albuminuria. Diabetes, 2002. 51(10): p. 3083-9. 96. Matsusaka, T., et al., Genetic engineering of glomerular sclerosis in the mouse via control of onset and severity of podocyte-specific injury. J Am Soc Nephrol, 2005. 16(4): p. 1013-23. 97. Lin, C.L., et al., MicroRNA-29a promotion of nephrin acetylation ameliorates hyperglycemia-induced podocyte dysfunction. J Am Soc Nephrol, 2014. 25(8): p. 1698-709. 98. Kato, H., et al., Wnt/beta-catenin pathway in podocytes integrates cell adhesion, differentiation, and survival. J Biol Chem, 2011. 286(29): p. 26003-15. 99. Eremina, V. and S.E. Quaggin, The role of VEGF-A in glomerular development and function. Curr Opin Nephrol Hypertens, 2004. 13(1): p. 9-15. 100. Lin, C.L., et al., Superoxide destabilization of beta-catenin augments apoptosis of high-glucose-stressed mesangial cells. Endocrinology, 2008. 149(6): p. 2934-42. 101. Lin, C.L., et al., Wnt/beta-catenin signaling modulates survival of high glucose-stressed mesangial cells. J Am Soc Nephrol, 2006. 17(10): p. 2812-20. 102. Lin, C.L., et al., Simvastatin reverses high glucose-induced apoptosis of mesangial cells via modulation of Wnt signaling pathway. Am J Nephrol, 2008. 28(2): p. 290-7. 103. Blattner, S.M., et al., Divergent functions of the Rho GTPases Rac1 and Cdc42 in podocyte injury. Kidney Int, 2013. 84(5): p. 920-30. 104. Gee, H.Y., et al., ARHGDIA mutations cause nephrotic syndrome via defective RHO GTPase signaling. J Clin Invest, 2013. 123(8): p. 3243-53. 105. Canaud, G., et al., AKT2 is essential to maintain podocyte viability and function during chronic kidney disease. Nat Med, 2013. 19(10): p. 1288-96. 106. Huber, T.B., et al., Emerging role of autophagy in kidney function, diseases and aging. Autophagy, 2012. 8(7): p. 1009-31. 107. Hartleben, B., et al., Autophagy influences glomerular disease susceptibility and maintains podocyte homeostasis in aging mice. J Clin Invest, 2010. 120(4): p. 1084-96. 108. Cheng, H.T., et al., Notch2, but not Notch1, is required for proximal fate acquisition in the mammalian nephron. Development, 2007. 134(4): p. 801-11. 109. Niranjan, T., et al., The Notch pathway in podocytes plays a role in the development of glomerular disease. Nat Med, 2008. 14(3): p. 290-8. 110. Lin, C.L., et al., Modulation of notch-1 signaling alleviates vascular endothelial growth factor-mediated diabetic nephropathy. Diabetes, 2010. 59(8): p. 1915-25. 111. Dai, C., et al., Wnt/beta-catenin signaling promotes podocyte dysfunction and albuminuria. J Am Soc Nephrol, 2009. 20(9): p. 1997-2008. 112. Huang, J.S., et al., Role of receptor for advanced glycation end-product (RAGE) and the JAK/STAT-signaling pathway in AGE-induced collagen production in NRK-49F cells. J Cell Biochem, 2001. 81(1): p. 102-13. 113. Guh, J.Y., et al., Advanced glycation end product-induced proliferation in NRK-49F cells is dependent on the JAK2/STAT5 pathway and cyclin D1. Am J Kidney Dis, 2001. 38(5): p. 1096-104. 114. Nihalani, D. and K. Susztak, Sirt1-Claudin-1 crosstalk regulates renal function. Nat Med, 2013. 19(11): p. 1371-2. 115. Duffield, J.S., et al., Host responses in tissue repair and fibrosis. Annu Rev Pathol, 2013. 8: p. 241-76. 116. Woroniecka, K.I., et al., Transcriptome Analysis of Human Diabetic Kidney Disease. Diabetes, 2011. 60(9): p. 2354-2369. 117. Anders, H.-J., et al., A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation. The Journal of Clinical Investigation, 2002. 109(2): p. 251-259. 118. Chavakis, T., A. Bierhaus, and P.P. Nawroth, RAGE (receptor for advanced glycation end products): a central player in the inflammatory response. Microbes Infect, 2004. 6(13): p. 1219-25. 119. Berthier, C.C., et al., Enhanced Expression of Janus Kinase–Signal Transducer and Activator of Transcription Pathway Members in Human Diabetic Nephropathy. Diabetes, 2009. 58(2): p. 469-477. 120. Sayyed, S.G., et al., An orally active chemokine receptor CCR2 antagonist prevents glomerulosclerosis and renal failure in type 2 diabetes. Kidney International, 2011. 80(1): p. 68-78. 121. Niewczas, M.A., et al., Circulating TNF Receptors 1 and 2 Predict ESRD in Type 2 Diabetes. Journal of the American Society of Nephrology, 2012. 23(3): p. 507-515. 122. Chuang, H.-Y., M. Hofree, and T. Ideker, A Decade of Systems Biology. Annual Review of Cell and Developmental Biology, 2010. 26(1): p. 721-744. 123. Komorowsky, C.V., et al., Perspectives on Systems Biology Applications in Diabetic Kidney Disease. Journal of Cardiovascular Translational Research, 2012. 5(4): p. 491-508. 124. Yardeni, T., et al., Retro-orbital injections in mice. Lab Anim (NY), 2011. 40(5): p. 155-60. 125. Rieg, T., A High-throughput method for measurement of glomerular filtration rate in conscious mice. J Vis Exp, 2013(75): p. e50330. 126. Weibel, E., Stereological methods. Practical methods for biological morphometry. Academic Press, 1979. 1: p. 9-62. 127. Takano, K., et al., Development of glomerular endothelial cells, podocytes and mesangial cells in the human fetus and infant. Tohoku J Exp Med, 2007. 212(1): p. 81-90. 128. Qi, Z., et al., Characterization of susceptibility of inbred mouse strains to diabetic nephropathy. Diabetes, 2005. 54(9): p. 2628-37. 129. King, A.J., The use of animal models in diabetes research. Br J Pharmacol, 2012. 166(3): p. 877-94. 130. Jerums, G., et al., The clinical significance of hyperfiltration in diabetes. Diabetologia, 2010. 53(10): p. 2093-104. 131. Helal, I., et al., Glomerular hyperfiltration: definitions, mechanisms and clinical implications. Nat Rev Nephrol, 2012. 8(5): p. 293-300. 132. Yang, G.K., et al., Renal hyperfiltration is associated with glucose-dependent changes in fractional excretion of sodium in patients with uncomplicated type 1 diabetes. Diabetes Care, 2014. 37(10): p. 2774-81. 133. Testagrossa, L., et al., Immunohistochemical expression of podocyte markers in the variants of focal segmental glomerulosclerosis. Nephrol Dial Transplant, 2013. 28(1): p. 91-8. 134. Trimarchi, H., Podocyturia: Potential applications and current limitations. World J Nephrol, 2017. 6(5): p. 221-228. 135. Breyer, M.D., et al., Mouse models of diabetic nephropathy. J Am Soc Nephrol, 2005. 16(1): p. 27-45. 136. Franzen, S., et al., Differences in susceptibility to develop parameters of diabetic nephropathy in four mouse strains with type 1 diabetes. Am J Physiol Renal Physiol, 2014. 306(10): p. F1171-8. 137. Qi, Z., et al., Serial determination of glomerular filtration rate in conscious mice using FITC-inulin clearance. Am J Physiol Renal Physiol, 2004. 286(3): p. F590-6. | - |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/70043 | - |
dc.description.abstract | 足細胞在腎絲球過濾屏障中扮演著不可或缺的角色,當足細胞病變或數目減少時會導致蛋白尿發生,長期下來會造成腎絲球硬化,喪失功能,產生末期腎病。隨著全球糖尿病患者的盛行率愈來愈高,糖尿病腎病(diabetic kidney disease;DKD)也越發普遍,目前臨床上常利用蛋白尿作為診斷與評估糖尿病腎病進展的指標,當尿蛋白增加時往往代表足細胞的損傷或功能已經出現異常;然而在蛋白尿升高之前,腎絲球早已承受超過率(hyperfiltration)與微血管內壓力增加多時。因此,如若能在蛋白尿發生之前,更早期地了解足細胞的基因、形態與功能變化,
對於一些急性或慢性腎病的早期發現、治療與預防策略是十分重要的。 根據過去的研究發現,在腎絲球損傷時足細胞會與周遭的細胞進行信號溝通相互影響,例如:腎絲球內皮細胞受損時可能會導致足細胞受傷脫落,而足細胞的功能異常與喪失也會造成內皮細胞死亡。此外,受損但未脫落的足細胞可能因為基因變異而釋放出不正常的訊號進一步導致足突消失(foot effacement)、脫落、肥大、凋亡等現象,這些情況都可能是急性腎損傷轉為慢性腎病亦或者是糖尿病演變成糖尿病腎病的關鍵原因,因此我們想要知道在急性腎損傷後以及早期糖尿病尚未出現蛋白尿時的足細胞基因表現變化並觀察這兩個時期的腎絲球與足細胞的形態變化。 首先我們利用Podocin-cre;itdTomato;iDTR的基因改造小鼠進行實驗。此小鼠表現Podocin基因的足細胞因會表現Cre 重組酶而活化紅色螢光蛋白(tdTomato)與人類白喉毒素受體(diphtheria toxin receptor;DTR),可藉此觀察腎絲球足細胞在損傷下的組織學變化,並有利於足細胞的分選收集與進一步分析。在急性腎絲球足細胞損傷的實驗中,我們給予特定劑量的白喉毒素注射後,小鼠約25%的足細胞會從基底膜上脫落,出現嚴重的蛋白尿(尿液中的白蛋白/肌酐酸比值會大幅上升),但經過一段時間之後蛋白尿的嚴重程度會減輕,推測腎絲球中尚未脫落之足細胞或許發生了代償變化以致出現某些機制來改善腎絲球過濾屏障的功能以降低蛋白尿,之後將會收集這些受損的足細胞去做微陣列分析來判斷基因發生了哪些改變,以利後續實驗來探索改善腎絲球足細胞的功能,減輕或延緩腎絲球硬化的進展。 我們接著進行腎絲球足細胞慢性損傷的實驗。一開始先利用野生種(wild type) C57BL/6小鼠,給予鏈脲佐菌素(Streptozotocin;STZ) 誘導小鼠血糖上升產生糖尿病。實驗結果顯示在STZ誘導5週之後,腎絲球過濾率會升高,腎絲球體積也會增加;然而,到STZ誘導10週時並未觀察到腎絲球出現硬化,於足細胞上也沒有發現脫落情形,在這段期間尿液中的鹽分濃度與蛋白尿程度也未觀察到變化。我們接著會利用Podocin-cre;itdTomato小鼠,在給予STZ之後第五週時收集這些受腎絲球超過濾影響的足細胞去做微陣列分析來判斷基因發生了哪些改變,以利後續實驗來探索改善腎絲球足細胞的功能,減輕或延緩腎絲球硬化的進展。 總結來說,急性足細胞凋亡或慢性腎絲球壓力增加都會對於存活的足細胞造成壓力並可能產生病變,最終會使得腎絲球過濾功能改變,並導致腎絲球後續硬化的進展。我們已建立急性與慢性腎絲球足細胞凋亡與壓力增加的動物模式,進一步的研究將可釐清足細胞在急性或慢性的壓力下,其代償或病生理的改變,是否可能成為更早期的治療標的,以防止腎絲球硬化的進行。 | zh_TW |
dc.description.abstract | Podocytes play an indispensable role in the glomerular filtration barrier. Podocytopathy or loss would lead to proteinuria, development of glomerulosclerosis, loss of glomerular filtration, and end stage renal disease (ESRD) in the long term. With the increasing prevalence of diabetic patients around the world, more and more diabetic kidney disease (DKD) arises. The occurrence of proteinuria always represents injury or dysfunction of glomerular filtration barrier, which has been applied to diagnose the progression of DKD in the past. However, glomerulus has already born hyperfiltration and rising capillary pressure for a long time before proteinuria occurred. Therefore, if we could unveil the changes of transcriptome, histology and function in podocytes early enough before proteinuria occurs, we would have a great chance to diagnose and treat glomerulopathy as early as possible.
Evidence has shown that podocytes will cross talk with surrounding cells including endothelial cells and mesangial cells while glomerulus is damaged. For instance, the injured glomerular endothelial cells may contribute to podocyte loss, and vice versa podocyte detachment could cause endothelial cell death. In addition, the podocytes may respond to injury by foot process effacement, hypertrophy, apoptosis or detachment from basement membrane, leading to transition of acute kidney injury into chronic kidney disease as well as the development of DKD in diabetes patients. Thus in this study, we would like to establish the models of acute podocyte ablation and glomerular hyperfiltration by specific genetic ablation and induction of diabetes mellitus respectively to unveil the response of the podocytes to acute injury or chronic hyperfiltration through transcriptome and histological analyses of podocytes. We first used Podocin-cre;itdTomato;iDTR genetically modified mice to carry out our experiments. The podocytes of the mice expressed Podocin gene could activate red fluorescence protein (tdTomato) and diphtheria toxin receptor (DTR) through Cre recombinase expressing. It is useful to observe the histological changes of glomerular podocytes after injury and to sort the cells by tdTomato expression. First, we carried out the experiments of acute podocyte injury by diphtheria toxin (DT) injection. After specific DT dose injected 14 days, 25% of glomerular podocytes would be ablated. Besides, severe proteinuria assessed by urine albumin/creatinine ratio would happen. Nevertheless, the proteinuria had improved since day 14 after DT injection, suggesting that surviving podocytes might have some compensatory mechanisms to improve glomerular filtration barrier and proteinuria. Next, we will sort these surviving podocytes to analyze the transcriptome by microarray. Secondly we carried out the experiments of chronic glomerular podocyte injury by inducing glomerular hyperfiltration. We first injected Streptozotocin (STZ) to wild type C57BL/6 mice in order to induce high blood sugar and diabetes. The results showed that the glomerular filtration rate assessed by inulin clearance raised and the glomerular volume increased 5 weeks after STZ injection. Nonetheless, the glomerulosclerosis and detachment of podocytes did not appear in Periodic acid-Schiff and immunofluorescence staining after STZ injected 10 weeks. Additionally, the urinary salt excretion and proteinuria did not change during the period. Next, we will use Podocin-cre;itdTomato mice for diabetes induction and sort the tdTomato+ podocytes at 5 weeks after STZ injection when hyperfiltration has happened and impacted on the podocytes. The sorted podocytes will be analyzed for transcriptome by microarray. Through these transcriptome analyses, we expect to unveil the mechanisms of surviving podocytes compensating the podocyte loss and the response of podocytes to hyperfiltration. In conclusion, acute podocytes apoptosis or chronic increase of glomerular pressure impact on the surviving podocytes. In the end, the glomerular filtration function would change and lead to subsequent progression of glomerulosclerosis. We have established the models of acute and chronic podocyte injuries, and we will use these models to unveil the mechanisms of podocytes compensating the cell loss and adapting to increased glomerular pressure in this study. We expect the study might provide early therapeutic targets to prevent glomerulosclerosis. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T03:40:24Z (GMT). No. of bitstreams: 1 ntu-107-R04441010-1.pdf: 4521968 bytes, checksum: 2a7a0f336829e41c4c61c9839761d7df (MD5) Previous issue date: 2018 | en |
dc.description.tableofcontents | 口試委員會審定書 i
誌謝 ii 摘要 iii Abstract v 目錄 viii 圖目錄 xii 表目錄 xiii 第一章 緒論 1 1.1 腎絲球 (Glomerulus) 1 1.1.1 構造 1 1.1.2 腎絲球過濾屏障(glomerular filtration barrier) 3 1.1.3 腎絲球硬化(glomerulosclerosis) 4 1.2 足細胞(podocyte) 5 1.2.1 形態與功能 5 1.2.2 足細胞與蛋白尿 6 1.2.3 足細胞受損時的變化 6 1.2.4 足細胞脫落的動物模型建立 7 1.3 血管內皮細胞(endothelial cell) 8 1.3.1 形態與功能 8 1.3.2 血管內皮細胞功能異常(endothelial cell dysfuction) 9 1.3.3 血管內皮細胞與足細胞的交互關係 10 1.4 足細胞損傷動物模式 11 1.4.1 急性損傷 11 1.4.2 慢性損傷 11 1.5 糖尿病腎病變 11 1.5.1 遺傳感受性 12 1.5.2 代謝異常的致病性 12 1.5.3 表觀遺傳誘發因子(epigenetic triggering factor) 13 1.5.4 內皮細胞功能失調的因素 13 1.5.5 足細胞的角色 14 1.5.6 發展路徑(developmental pathway)的異常活化 14 1.5.7 發炎性路徑的角色 15 1.5.8 展望糖尿病腎病變的病生理機轉:未來趨勢 15 1.6 實驗目的 16 第二章 材料與方法 17 2.1 材料 17 2.1.1 實驗動物 17 2.1.2 白喉毒素(Diphtheria toxin;DT) 18 2.1.3 藥品與試劑 18 2.1.4 溶液 22 2.1.5 抗體 24 2.2 方法 26 2.2.1 小鼠基因型鑑定 26 2.2.2 足細胞脫落老鼠模型(急性損傷) 27 2.2.3 糖尿病老鼠模型(慢性損傷) 27 2.2.4 檢體採集 27 2.2.5 腎絲球的足細胞與內皮細胞分離 28 2.2.6 血壓測量 29 2.2.7 腎絲球過濾率測量 29 2.2.8 免疫螢光染色(immunofluorescence;IF) 30 2.2.9 足細胞脫落比例計算 30 2.2.10 腎絲球體積計算 31 2.2.11 統計分析 31 第三章 實驗結果 32 3.1 DT誘導小鼠產生短暫的蛋白尿,具有dose-dependent關係 32 3.2 DT對腎臟生理功能的影響 33 3.3 在DT誘導下,足細胞的WT1表現會漸漸消失 33 3.4 表現iDTR的足細胞會受DT誘導而脫落,且脫落程度與DT劑量成正比 34 3.5 DT劑量1 ng/g可造成25-50%足細胞脫落 35 3.6 DT造成腎絲球組織結構改變 35 3.7 DT造成的足細胞急性損傷並不會導致腎絲球出現纖維化 36 3.8 腎絲球內的足細胞與內皮細胞分離與收集 36 3.9 利用STZ誘導糖尿病產生 37 3.10 糖尿病早期的生理變化 37 3.11 STZ誘導後5週腎絲球出現hyperfiltration 38 3.12 Hyperfiltration與尿液中的鹽分變化 39 3.13 糖尿病早期出現hyperfiltration後的腎絲球組織變化 40 3.14 糖尿病早期出現hyperfiltration後,足細胞並未出現脫落,WT1的表現也不會受到影響 41 3.15 收集糖尿病早期腎絲球內的足細胞與內皮細胞 41 第四章 討論 42 4.1 DT造成的ACR高升情形在經過高峰期後會漸漸恢復 42 4.2 DT誘導下造成足細胞WT1表現逐漸喪失 43 4.3 DT誘導足細胞脫落之後沒有觀察到硬化出現 43 4.4 STZ的作用對腎臟是否造成傷害 44 4.5 C57BL/6老鼠在糖尿病誘導下的生理變化 44 4.6 Hyperfiltration無繼續維持上升,尿液中的鹽分濃度也沒有變低 46 4.7 足細胞與內皮細胞的收集方法改善 47 4.8 未來可進行的相關實驗 47 第五章 結論與未來展望 48 圖表 49 附錄 72 補充 73 第六章 參考文獻 74 | - |
dc.language.iso | zh_TW | - |
dc.title | 腎絲球足細胞在急性與慢性足細胞損傷中的變化 | zh_TW |
dc.title | The response of glomerular podocytes to acute and chronic podocyte injury | en |
dc.type | Thesis | - |
dc.date.schoolyear | 106-1 | - |
dc.description.degree | 碩士 | - |
dc.contributor.oralexamcommittee | 陳永銘;姜文智 | zh_TW |
dc.contributor.oralexamcommittee | ;; | en |
dc.subject.keyword | 腎絲球,足細胞,蛋白尿,糖尿病腎病,腎絲球過濾率, | zh_TW |
dc.subject.keyword | glomerulus,podocyte,proteinuria,diabetic kidney disease,hyperfiltration, | en |
dc.relation.page | 82 | - |
dc.identifier.doi | 10.6342/NTU201800418 | - |
dc.rights.note | 未授權 | - |
dc.date.accepted | 2018-02-08 | - |
dc.contributor.author-college | 醫學院 | - |
dc.contributor.author-dept | 生理學研究所 | - |
顯示於系所單位: | 生理學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-106-1.pdf 目前未授權公開取用 | 4.42 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。